Double attack on deadly melanoma shows promise
NCT ID NCT04889118
Summary
This completed Phase 3 trial tested whether adding the drug lenvatinib to the immunotherapy pembrolizumab works better than pembrolizumab alone for Chinese patients with advanced melanoma that has spread. The study involved 131 participants who had not received prior drug treatment for their advanced cancer. Researchers measured how long patients lived without their cancer getting worse and their overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital (0601)
Beijing, Beijing Municipality, 100036, China
-
Fudan University Shanghai Cancer Center ( Site 0607)
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Provincial Cancer Hospital ( Site 0612)
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital ( Site 0610)
Zhengzhou, Henan, 450003, China
-
Nanjing Drum Tower Hospital (0609)
Nanjing, Jiangsu, 210008, China
-
Sir Run Run Shaw Hospital (0605)
Hangzhou, Zhejiang, 310018, China
-
Sun Yat-Sen University Cancer Center (0602)
Guangzhou, Guangdong, 510000, China
-
The First Hospital Of Jilin University (0603)
Changchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital (0606)
Tianjin, Tianjin Municipality, 300060, China
-
Yunnan Cancer Hospital (0604)
Kunming, Yunnan, 430030, China
-
Zhejiang Cancer Hospital ( Site 0608)
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.